Anika Therapeutics, Inc. announced the full market release of their novel RevoMotion™ Reverse Shoulder Arthroplasty System which, among other features, brings to the surgeon a 23mm diameter baseplate, the smallest threaded baseplate on the market.
New Shoulder System Features Smallest Baseplate Yet
2 min read Premium comments
Secondary#anikatherapeutics#revomotion
The importance of a smaller profile baseplate was highlighted at the recent 2023 Orthopaedic Summit Evolving Technologies (OSET) meeting by Christopher Baker, M.D., Florida Orthopaedic Institute, Tampa, Florida who said, “A 23mm diameter baseplate, the smallest threaded baseplate on the market, allows me the potential to save glenoid bone-stock and provides flexibility in positioning, so that I can treat a variety of glenoid morphologies.”
Furthermore, said Dr. Baker, “With short term follow-up we are seeing tremendous satisfaction from our patients and improving pain and function.”
Anika, a Global Joint Preservation Company
Bedford, Massachusetts-based Anika Therapeutics, which built its reputation among orthopedic surgeons as an hyaluronic acid (HA) knee injection company, has expanded significantly under President and CEO Cheryl Blanchard and now offers, for example, a full range of innovative shoulder arthroplasty, bone conserving solutions.
In addition to RevoMotion, Anika is providing extremity surgeons with a full continuum of rotator cuff disease treatments including the recently launched X-Twist™ Fixation System and newly cleared Integrity™ regenerative hyaluronic acid-based patch system launching in Q1-2024
Blanchard said this at the recent OSET meeting: “We’re excited to participate in this year’s OSET Annual Meeting, where we are showcasing our breakthrough new products focused on early intervention orthopedics, including the launch of our RevoMotion Reverse Shoulder Arthroplasty System, designed specifically to address clinical needs through a truly bone preserving design with simple and efficient instrumentation.”
In addition, said Blanchard, “We are also previewing our recently cleared Integrity regenerative HA-based rotator cuff patch system, which is uniquely strong, versatile, and easy-to-use. Integrity has an innovative delivery and fixation system and has greater regenerative capacity compared to first generation collagen patches.”
RevoMotion
According to Anika, the key features and benefits of RevoMotion are:
- Industry’s smallest diameter threaded glenoid baseplate in order to better preserve bone, provide flexibility in positioning and maximizing fixation of the glenoid components, all while achieving substantial fixation via a central compression screw.
- Mid-lay Humeral Implant: Partially in-lay and partially on-lay, with seven humeral tray sizes which provide a more precise fit and is designed to optimize range of motion and reduce risk of scapular notching. The humeral tray and bone preparation are designed to decrease stress shielding on the proximal humerus with forces evenly distributed across entire proximal humerus.
- Preserve bone and personalize to the patient. The system’s bone preserving glenoid and humeral designs provide patient personalization by way of numerous humeral tray offerings which match the native anatomy. This approach is similar to Anika’s other implant system designs in the Arthrosurface Joint Solutions portfolio including the flagship OVOMotion® with Inlay Glenoid Total Shoulder Arthroplasty System.
- More surgeon and facility efficiency. With two streamlined instrument trays, RevoMotion optimizes surgeon and facility efficiency. The consolidated instrumentation is both Ambulatory Surgery Center (ASC) and hospital friendly. Smaller back table footprint, reduced sterile reprocessing and, compared with more complex designs currently on the market, more affordable.
For more information: www.anika.com
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.